RxDoctor Payments Data

Phillip Liaw, MD

Internal Medicine · Feasterville Trevose, PANPI 1245248442

Payments from drug & device makers

$3,658in general payments, 2019–2025

Across 223 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$832
  • AstraZeneca$483
  • Pfizer$371
  • Lilly USA, LLC$271
  • Boehringer Ingelheim$169
  • Bayer$157
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,641100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,658 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$61,124
Medicare patients
294
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$130,229
EliquisApixaban134$103,582
JardianceEmpagliflozin60$52,972
TrulicityDulaglutide27$45,173
FarxigaDapagliflozin Propanediol34$39,454
MounjaroTirzepatide36$36,752
VraylarCariprazine Hcl26$36,013
JanuviaSitagliptin Phosphate21$34,318
XareltoRivaroxaban26$22,027
TradjentaLinagliptin13$17,282
NexletolBempedoic Acid20$14,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,021
VascepaIcosapent Ethyl36$11,813
Atorvastatin Calcium536$7,556
Humalog Kwikpen U-100Insulin Lispro11$6,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$832$130,22983 claims
PfizerEliquis$371$103,582134 claims
Lilly USA, LLCTrulicity, Mounjaro$271$81,92463 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$169$76,37286 claims
MerckJanuvia, Janumet Xr$74$40,23537 claims
AstraZenecaFarxiga$483$39,45434 claims
AbbVieVraylar, Synthroid$141$37,85275 claims
Johnson & JohnsonXarelto$27$22,02726 claims
Esperion Therapeutics, Inc.Nexletol$133$14,05220 claims
GSKTrelegy Ellipta$17$14,02122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Feasterville Trevose

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →